Baseline characteristics of patients randomised to IDEA-033, celecoxib, or placebo
| Characteristic | IDEA-033 (n = 138) | Celecoxib (n = 132) | Placebo (n = 127) | |
|---|---|---|---|---|
| PGA, physician’s global assessment; WOMAC, Western Ontario and McMaster Universities. | ||||
| *One patient did not provide a baseline physical function score (n = 137). | ||||
| †All WOMAC subscale scores were normalised to a scale of 0 to 100 by dividing the sum subscale score by the number of questions of each subscale score. | ||||
| Values are numbers (percentages) unless stated otherwise. | ||||
| Mean (SD) age (years) | 63.3 (10.1) | 62.4 (9.6) | 62.8 (9.8) | |
| Men | 63 (45.7) | 50 (37.9) | 47 (37.0) | |
| Women | 75 (54.3) | 82 (62.1) | 80 (63.0) | |
| WOMAC Index | ||||
| Mean (SD) pain score† | 55.1 (18.4) | 56.1 (18.6) | 59.9 (17.3) | |
| Mean (SD) stiffness score† | 49.4 (21.1) | 50.6 (22.2) | 53.1 (21.1) | |
| Mean (SD) physical function score† | 53.8 (20.4)* | 54.6 (21.0) | 58.9 (19.6) | |
| Mean (SD) PGA of osteoarthritis | 3.9 (0.5) | 3.9 (0.6) | 4.0 (0.5) | |